COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications

Simple item page
dc.contributor.authorAl Mahmasani, Layal
dc.contributor.authorHodroj, Mohammad Hassan
dc.contributor.authorFinianos, Antoine
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:01:03Z
dc.date.available2025-01-24T12:01:03Z
dc.date.issued2021
dc.description.abstractCOVID-19 pandemic has imposed worldwide challenge and has significantly affected transfusion medicine. Shortage in blood products along with concerns regarding the safety of blood products have emerged. Measures to overcome these challenges have been implemented in order to decrease the demand on blood products and to encourage blood donations while taking full precautions to minimize risk of COVID-19 transmission mainly at blood banks and medical centers. Several countries have been successful in facing these new challenges. In addition, the role of plasma therapy in the treatment of COVID-19 patients, especially in severe cases, has been proposed and current studies are being conducted to determine its efficacy. Other therapeutic options are currently being explored. So far, the use of convalescent plasma is considered a promising rescue treatment to be looked at. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
dc.identifier.doihttps://doi.org/10.1007/s00277-021-04441-y
dc.identifier.eid2-s2.0-85100080020
dc.identifier.pmid33527161
dc.identifier.urihttp://hdl.handle.net/10938/31436
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofAnnals of Hematology
dc.sourceScopus
dc.subjectBlood safety
dc.subjectCovid-19
dc.subjectPlasma therapy
dc.subjectShortage
dc.subjectTransfusion
dc.subjectBlood donors
dc.subjectHumans
dc.subjectImmunization, passive
dc.subjectTransfusion medicine
dc.subjectTreatment outcome
dc.subjectAdalimumab
dc.subjectBevacizumab
dc.subjectCamrelizumab
dc.subjectChloroquine
dc.subjectCorticosteroid
dc.subjectEculizumab
dc.subjectFingolimod
dc.subjectFresh frozen plasma
dc.subjectHydroxychloroquine
dc.subjectIxekizumab
dc.subjectLopinavir plus ritonavir
dc.subjectPirfenidone
dc.subjectRecombinant interleukin 2
dc.subjectRemdesivir
dc.subjectSarilumab
dc.subjectSars-cov-2 convalescent plasma
dc.subjectThalidomide
dc.subjectBiosafety
dc.subjectBlood donor
dc.subjectClinical effectiveness
dc.subjectClinical feature
dc.subjectClinical practice
dc.subjectCoronavirus disease 2019
dc.subjectDisease transmission
dc.subjectEpidemiological data
dc.subjectHealth care availability
dc.subjectHuman
dc.subjectInfection risk
dc.subjectMesenchymal stem cell transplantation
dc.subjectNonhuman
dc.subjectPandemic
dc.subjectPlasma transfusion
dc.subjectPractice guideline
dc.subjectReverse transcription polymerase chain reaction
dc.subjectReview
dc.subjectTreatment planning
dc.subjectAdverse event
dc.subjectEpidemiology
dc.subjectPassive immunization
dc.subjectProcedures
dc.subjectTherapy
dc.titleCOVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-6046.pdf
Size:
256.82 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine